Qing Yi

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. pmc Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
    Siqing Wang
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:4071-7. 2006
  2. ncbi request reprint Optimizing dendritic cell-based immunotherapy in multiple myeloma
    Qing Yi
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 117:297-305. 2002
  3. ncbi request reprint Dendritic cell-based immunotherapy in multiple myeloma
    Qing Yi
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 776, Little Rock, AR 72205, USA
    Leuk Lymphoma 44:2031-8. 2003
  4. ncbi request reprint Immunotherapy in multiple myeloma: current strategies and future prospects
    Qing Yi
    Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Expert Rev Vaccines 2:391-8. 2003
  5. ncbi request reprint Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
    Jianfei Qian
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Clin Cancer Res 11:8808-15. 2005
  6. ncbi request reprint Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells
    Jin Xie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Ark, USA
    Exp Hematol 33:564-72. 2005
  7. ncbi request reprint Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
    Yue Jin Wen
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, Little Rock 72205, USA
    Blood 99:3280-5. 2002
  8. ncbi request reprint Cancer and the microenvironment: myeloma-osteoclast interactions as a model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR 72205, USA
    Cancer Res 64:2016-23. 2004
  9. ncbi request reprint Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38
    Jin Xie
    Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, Little Rock 72205, USA
    J Immunol 171:4792-800. 2003
  10. ncbi request reprint Beta(2)-microglobulin as a negative growth regulator of myeloma cells
    Rui Min
    Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 118:495-505. 2002

Collaborators

Detail Information

Publications23

  1. pmc Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
    Siqing Wang
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:4071-7. 2006
    ..Thus, this study has delineated the mechanistic defects of MoDCs from myeloma patients and identified ways for restoring the function of the cells to improve the efficacy of DC-based immunotherapy in this disease...
  2. ncbi request reprint Optimizing dendritic cell-based immunotherapy in multiple myeloma
    Qing Yi
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 117:297-305. 2002
    ..Current efforts are geared towards optimizing the conditions of DC generation and administration, and the development of in vitro assays to monitor the cytotoxicity of the T cells...
  3. ncbi request reprint Dendritic cell-based immunotherapy in multiple myeloma
    Qing Yi
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 776, Little Rock, AR 72205, USA
    Leuk Lymphoma 44:2031-8. 2003
    ..I will discuss myeloma antigens and antigen-specific immune responses, the capacity of DCs to present myeloma antigens and induce cytotoxic T-cell responses, and clinical experience of DC vaccination in myeloma patients...
  4. ncbi request reprint Immunotherapy in multiple myeloma: current strategies and future prospects
    Qing Yi
    Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Expert Rev Vaccines 2:391-8. 2003
    ..Various strategies of immunotherapy and the outcome of clinical trials are also discussed...
  5. ncbi request reprint Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
    Jianfei Qian
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Clin Cancer Res 11:8808-15. 2005
    ..Recent studies in solid tumors show that tumor-derived heat shock proteins (Hsp) can be used as immunogen; however, no such study has yet been reported in multiple myeloma...
  6. ncbi request reprint Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells
    Jin Xie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Ark, USA
    Exp Hematol 33:564-72. 2005
    ..The aim of this study is to investigate the signaling pathways and their roles in the differentiation of immature monocyte-derived dendritic cells (MoDCs)...
  7. ncbi request reprint Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
    Yue Jin Wen
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, Little Rock 72205, USA
    Blood 99:3280-5. 2002
    ..These findings represent the first demonstration that tumor cell lysate-primed CTLs kill only myeloma cells, not autologous lymphocytes. This provides a rationale for myeloma cell-based immunotherapy in multiple myeloma...
  8. ncbi request reprint Cancer and the microenvironment: myeloma-osteoclast interactions as a model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR 72205, USA
    Cancer Res 64:2016-23. 2004
    ..These results support data obtained from animal models and clinical observations on the essential role of the microenvironment in tumor sustenance and progression...
  9. ncbi request reprint Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38
    Jin Xie
    Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, Little Rock 72205, USA
    J Immunol 171:4792-800. 2003
    ..Thus, our study reveals that LPS has dual effects on DCs that are biologically important: activating existing DCs to initiate an immune response, and inhibiting the generation of new DCs to limit such a response...
  10. ncbi request reprint Beta(2)-microglobulin as a negative growth regulator of myeloma cells
    Rui Min
    Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 118:495-505. 2002
    ....
  11. ncbi request reprint Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells
    Jin Xie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 101:4005-12. 2003
    ....
  12. ncbi request reprint Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma
    Siqing Wang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer, Houston, Texas 77030, USA
    Front Biosci 12:3566-75. 2007
    ..Further studies are needed to optimize methods of DC-based vaccines to improve the efficacy of clinical trials...
  13. ncbi request reprint Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond
    Yuhong Zhou
    Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
    Am J Hematol 83:144-9. 2008
    ..A Phase I/II study is ongoing to determine the maximum tolerated dose (MTD) and the efficacy of lenalidomide in combination with Rituximab for relapsed/refractory MCL. This review summarizes the latest and exciting advances in MCL...
  14. pmc Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:1587-94. 2007
    ..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM...
  15. pmc Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma
    Siqing Wang
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:2432-9. 2006
    ....
  16. ncbi request reprint Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 12:252-65. 2007
    ..CRP also enhanced myeloma cell secretion of IL-6 and synergized with IL-6 to protect myeloma cells from chemotherapy drug-induced apoptosis. Thus, our results implicate CRP as a potential target for cancer treatment...
  17. ncbi request reprint Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation
    Yuan Pei
    State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China
    J Immunol 180:222-9. 2008
    ..In vivo and in vitro data support a model in which CD28 costimulation activates AKT to phosphorylate NF90 at Ser647 and phosphorylation triggers NF90 to relocate to the cytoplasm and stabilize IL-2 mRNA...
  18. ncbi request reprint Transforming and secreting expression of human egf in mutant strain WYBS2001 of Bacillus and its functions
    Guan Lin Wang
    College of Life Science, Liaoning Normal University, Dalian 116029, China
    Yi Chuan Xue Bao 30:97-102. 2003
    ..WYBS2001T engineering strain had obvious effect on healing the burned animals' models. This research showed microecological gene-engineering bacteria has good applying foreground...
  19. pmc Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:3028-35. 2007
    ..Thus, this study further defines the tumoricidal mechanism of the mAbs and provides strong evidence to support the potential of these mAbs as therapeutic agents for myeloma...
  20. ncbi request reprint Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies
    Jing Yang
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 10:295-307. 2006
    ..Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies...
  21. ncbi request reprint Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies
    Qing Yi
    Clin Cancer Res 11:966-7. 2005
  22. ncbi request reprint Beta2-microglobulin as a potential initiator of inflammatory responses
    Jin Xie
    Trends Immunol 24:228-9; author reply 229-30. 2003
  23. pmc Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth
    Sungyoul Hong
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:8456-64. 2008
    ..These results show that Id-specific CTL and Th1 are promising effector cells, whereas Th2 provide no protection and may even promote tumor progression in vivo...